The present invention relates to a pharmaceutical combination which comprises (a) an mTOR catalytic inhibitor, such as a catalytic phosphatidylinositol-3-kinase (PI3K) and mTOR inhibitor compound which is an imidazoquinoline derivative and (b) at least one allosteric mTOR inhibitor compound, and optionally, at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use, in particular for the treatment of an mammalian target of rapamycin (mTOR) kinase dependent proliferative diseases； and the uses of such a combination in the treatment of mTOR kinase dependent proliferative diseases； a pharmaceutical composition comprising such a combination； the use of such a combination for the preparation of a medicament for the treatment of a proliferative disease； a commercial package or product comprising such a combination as a combined preparation for simultaneous, separate or sequential use； and to a method of treatment of a warm-blooded animal, especially a human.
